Stocklytics Platform
Asset logo for symbol MNKD
MannKind
MNKD
83
$4.78arrow_drop_up0.63%$0.03
High Quality
High Growth
Penny Stock

Performance History

Chart placeholder
Key Stats
Open$4.76
Prev. Close$4.75
EPS0.04
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap1307116800.00
PE Ratio119.50
LOWHIGH
Day Range4.72
4.82
52 Week Range3.17
5.75
Ratios
P/B Ratio0.00
Revenue$198.96M
Operating M. %23.13%
Earnings$0.00
Earnings Growth %86.34%
EBITDA Margin %18.00%
ROE %0.00%
EPS0.04

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$891.46
Perf. (24h)
arrow_drop_up0.72%$6.45
Market Cap$834.88B
Price$481.04
Perf. (24h)
0.00%$0.00
Market Cap$451.06B
Price$145.64
Perf. (24h)
arrow_drop_down0.20%-$0.30
Market Cap$350.26B
Price$127.99
Perf. (24h)
arrow_drop_up0.38%$0.49
Market Cap$327.94B

About MannKind (MNKD)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Michael E. Castagna Pharm.D.
Headquarters
Danbury
Employees
391
Exchange
NASDAQ
add MannKind to watchlist

Keep an eye on MannKind

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is MannKind's (MNKD) price per share?

The current price per share for MannKind (MNKD) is $4.78. The stock has seen a price change of $0.03 recently, indicating a 0.63% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for MannKind (MNKD)?

For MannKind (MNKD), the 52-week high is $5.75, which is 20.29% from the current price. The 52-week low is $3.17, the current price is 50.79% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is MannKind (MNKD) a growth stock?

MannKind (MNKD) has shown an average price growth of 0.41% over the past three years. It has received a score of 50 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying MannKind as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is MannKind (MNKD) stock price performance year to date (YTD)?

As of the latest data, MannKind (MNKD) has a year-to-date price change of 21.94%. Over the past month, the stock has experienced a price change of 1.7%. Over the last three months, the change has been 3.46%. Over the past six months, the figure is 28.15%. Looking at a longer horizon, the five-year price change stands at 293.42%.

help
Is MannKind (MNKD) a profitable company?

MannKind (MNKD) has a net income of -$11.94M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 68.45% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 23.13% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $198.96M, with a revenue growth rate of 99.42%, providing insight into the company's sales performance and growth. The gross profit is $136.19M. Operating income is noted at $10.59M. Furthermore, the EBITDA is $45.39M.

help
What is the market capitalization of MannKind (MNKD)?

MannKind (MNKD) has a market capitalization of $1.31B. The average daily trading volume is 2.26M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level